collection
https://read.qxmd.com/read/32102926/albumin-in-decompensated-cirrhosis-new-concepts-and-perspectives
#1
REVIEW
Mauro Bernardi, Paolo Angeli, Joan Claria, Richard Moreau, Pere Gines, Rajiv Jalan, Paolo Caraceni, Javier Fernandez, Alexander L Gerbes, Alastair J O'Brien, Jonel Trebicka, Thierry Thevenot, Vicente Arroyo
The pathophysiological background of decompensated cirrhosis is characterised by a systemic proinflammatory and pro-oxidant milieu that plays a major role in the development of multiorgan dysfunction. Such abnormality is mainly due to the systemic spread of bacteria and/or bacterial products from the gut and danger-associated molecular patterns from the diseased liver triggering the release of proinflammatory mediators by activating immune cells. The exacerbation of these processes underlies the development of acute-on-chronic liver failure...
June 2020: Gut
https://read.qxmd.com/read/30730782/full-study-report-of-andexanet-alfa-for-bleeding-associated-with-factor-xa-inhibitors
#2
JOURNAL ARTICLE
Stuart J Connolly, Mark Crowther, John W Eikelboom, C Michael Gibson, John T Curnutte, John H Lawrence, Patrick Yue, Michele D Bronson, Genmin Lu, Pamela B Conley, Peter Verhamme, Jeannot Schmidt, Saskia Middeldorp, Alexander T Cohen, Jan Beyer-Westendorf, Pierre Albaladejo, Jose Lopez-Sendon, Andrew M Demchuk, Daniel J Pallin, Mauricio Concha, Shelly Goodman, Janet Leeds, Sonia Souza, Deborah M Siegal, Elena Zotova, Brandi Meeks, Sadia Ahmad, Juliet Nakamya, Truman J Milling
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexanet, followed by a 2-hour infusion. The coprimary outcomes were the percent change in anti-factor Xa activity after andexanet treatment and the percentage of patients with excellent or good hemostatic efficacy at 12 hours after the end of the infusion, with hemostatic efficacy adjudicated on the basis of prespecified criteria...
April 4, 2019: New England Journal of Medicine
https://read.qxmd.com/read/30701448/current-use-of-vasopressors-in-septic-shock
#3
JOURNAL ARTICLE
Thomas W L Scheeren, Jan Bakker, Daniel De Backer, Djillali Annane, Pierre Asfar, E Christiaan Boerma, Maurizio Cecconi, Arnaldo Dubin, Martin W Dünser, Jacques Duranteau, Anthony C Gordon, Olfa Hamzaoui, Glenn Hernández, Marc Leone, Bruno Levy, Claude Martin, Alexandre Mebazaa, Xavier Monnet, Andrea Morelli, Didier Payen, Rupert Pearse, Michael R Pinsky, Peter Radermacher, Daniel Reuter, Bernd Saugel, Yasser Sakr, Mervyn Singer, Pierre Squara, Antoine Vieillard-Baron, Philippe Vignon, Simon T Vistisen, Iwan C C van der Horst, Jean-Louis Vincent, Jean-Louis Teboul
BACKGROUND: Vasopressors are commonly applied to restore and maintain blood pressure in patients with sepsis. We aimed to evaluate the current practice and therapeutic goals regarding vasopressor use in septic shock as a basis for future studies and to provide some recommendations on their use. METHODS: From November 2016 to April 2017, an anonymous web-based survey on the use of vasoactive drugs was accessible to members of the European Society of Intensive Care Medicine (ESICM)...
January 30, 2019: Annals of Intensive Care
https://read.qxmd.com/read/30643933/10-myths-about-frusemide
#4
EDITORIAL
Michael Joannidis, Sebastian J Klein, Marlies Ostermann
No abstract text is available yet for this article.
April 2019: Intensive Care Medicine
https://read.qxmd.com/read/30630521/early-diuretic-use-and-mortality-in-critically-ill-patients-with-vasopressor-support-a-propensity-score-matching-analysis
#5
JOURNAL ARTICLE
Yanfei Shen, Weimin Zhang, Yong Shen
BACKGROUND: The effect of loop diuretic use in critically ill patients on vasopressor support or in shock is unclear. This study aimed to explore the relationship between loop diuretic use and hospital mortality in critically ill patients with vasopressor support. METHODS: Data were extracted from the Medical Information Mart for Intensive Care III database. Adult patients with records of vasopressor use within 48 h after intensive care unit admission were screened...
January 10, 2019: Critical Care: the Official Journal of the Critical Care Forum
https://read.qxmd.com/read/30626586/sepsis-associated-acute-kidney-injury
#6
REVIEW
Jason T Poston, Jay L Koyner
Sepsis is defined as organ dysfunction resulting from the host's deleterious response to infection. One of the most common organs affected is the kidneys, resulting in sepsis associated acute kidney injury (SA-AKI) that contributes to the morbidity and mortality of sepsis. A growing body of knowledge has illuminated the clinical risk factors, pathobiology, response to treatment, and elements of renal recovery that have advanced our ability to prevent, detect, and treat SA-AKI. Despite these advances, SA-AKI remains an important concern and clinical burden, and further study is needed to reduce the acute and chronic consequences...
January 9, 2019: BMJ: British Medical Journal
https://read.qxmd.com/read/30606404/epidemiology-pathophysiology-and-management-of-hepatorenal-syndrome
#7
REVIEW
Ahmed Adel Amin, Eman Ibrahim Alabsawy, Rajiv Jalan, Andrew Davenport
Acute kidney injury (AKI) is a common presentation in patients with advanced cirrhosis hospitalized with acute decompensation. A new revised classification now divides AKI in cirrhotic patients into two broad subgroups: hepatorenal syndrome AKI (HRS AKI) and non-hepatorenal syndrome AKI (non-HRS AKI). HRS AKI represents the end-stage complication of decompensated cirrhosis with severe portal hypertension and is characterized by worsening of renal function in the absence of prerenal azotemia, nephrotoxicity, and intrinsic renal disease...
January 2019: Seminars in Nephrology
https://read.qxmd.com/read/20200382/comparison-of-dopamine-and-norepinephrine-in-the-treatment-of-shock
#8
RANDOMIZED CONTROLLED TRIAL
Daniel De Backer, Patrick Biston, Jacques Devriendt, Christian Madl, Didier Chochrad, Cesar Aldecoa, Alexandre Brasseur, Pierre Defrance, Philippe Gottignies, Jean-Louis Vincent
BACKGROUND: Both dopamine and norepinephrine are recommended as first-line vasopressor agents in the treatment of shock. There is a continuing controversy about whether one agent is superior to the other. METHODS: In this multicenter, randomized trial, we assigned patients with shock to receive either dopamine or norepinephrine as first-line vasopressor therapy to restore and maintain blood pressure. When blood pressure could not be maintained with a dose of 20 microg per kilogram of body weight per minute for dopamine or a dose of 0...
March 4, 2010: New England Journal of Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.